1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY TECHNIQUE
5.1. Introduction
5.2. In Vitro Fertilization (IVF)
5.3. Artificial Insemination (AI)
5.4. Frozen Embryo Transfer (FET)
5.5. Surrogacy
5.6. Others
6. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY PROCEDURE
6.1. Introduction
6.2. Fresh Donor
6.3. Fresh Non-Donor
6.4. Frozen Donor
6.5. Frozen Non-Donor
7. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY END-USER
7.1. Introduction
7.2. Hospitals
7.3. Fertility Clinics
7.4. Cryobanks
7.5. Research Institutes
8. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Technique
8.2.2. By Procedure
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Technique
8.3.2. By Procedure
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Technique
8.4.2. By Procedure
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.2. Germany
8.4.4.3. France
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Technique
8.5.2. By Procedure
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Technique
8.6.2. By Procedure
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. India
8.6.4.4. South Korea
8.6.4.5. Taiwan
8.6.4.6. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. FUJIFILM Irvine Scientific
10.2. Merck KGaA
10.3. Vitrolife AB
10.4. CooperSurgical, Inc.
10.5. Thermo Fisher Scientific Inc.
10.6. Cook Medical
10.7. Genea Biomedx
10.8. IMV Technologies
10.9. Ferring Pharmaceuticals
10.10. IVFtech ApS
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES